Discussion Paper. On Friday June 24, the PMPRB released a long delayed discussion paper covering a wide range of issues that go to the core of the PMPRB’s price regulation mandate. The PMPRB will be seeking input from stakeholders over the Summer/Fall of 2016 and will hold public policy hearings ... Read More
27
Jun2016
03
May2016
The Patented Medicine Prices Review Board (PMPRB) has released its April 2016 NEWSletter. Some recent changes include:
Public Consultation on PMPRB Framework Modernization
In December 2015, the PMPRB released its 2015-2018 Strategic Plan, the culmination of a year-long strategic planning process that identified a new vision, a revised mission statement, and four ... Read More
24
Mar2016
In December 2015, the Patented Medicine Prices Review Board (PMPRB) posted a Notice and Comment seeking stakeholder comments on the following proposed changes:
Reasonable Relationship Test (Schedule 4) Amendment
List Price relative to Maximum Average Potential Price (MAPP) Verification (Section C.11) Amendment
Subsequent to stakeholder feedback received during the public comment period, ... Read More
12
Feb2016
As part of the National Prescription Drug Utilization Information System (NPDUIS), the Patented Medicine Prices Review Board (PMPRB) has recently released a report entitled, Generics360 – Generic Drugs in Canada, 2014.
Through this newly named report series, the PMPRB monitors and reports on:
the latest developments in generic drug pricing and markets ... Read More
21
Dec2015
The Patented Medicines Prices Review Board (PMPRB) has released their highly anticipated Strategic Plan 2015-2018. The PMPRB’s three-year strategic plan includes four new strategic objectives, a reinvigorated mission statement, and a vision as to how the organization can work with partners and stakeholders in advancing the common goal of ... Read More
14
Dec2015
The Patented Medicine Prices Review Board (PMPRB), in accordance with sections 89 and 100 of the Patent Act, has released the Annual Report for the year ended December 31, 2014. This year, the format has been updated, adopting a more user-friendly design highlighting the PMPRB activities and emphasizing important trends.
Below ... Read More
13
Nov2015
2015 FCA 249 Attorney General of Canada v Sandoz (A-302-14) & v ratiopharm (now Teva) (A-303-14).
The central issue in both appeals is whether the Federal Court judge properly held that Sandoz and ratiopharm (collectively the respondents) fell outside of the jurisdiction of the Board as they were not “patentees” within ... Read More
31
Jul2015
Topics covered in the NEWSletter include:
Soliris Pre-Hearing Conference
New Staff Member – Legal Services
Update: Compendium of Policies, Guidelines and Procedures
Part C – Guidelines and Procedures
Schedule 9 – CPI-Adjustment Methodology
Schedule 2 – Comparable Dosage Forms
2016 HDAP Meeting Schedule & Filing Requirements:
February 29
May 2
September 12
November 28
PMPRB Transition to Canada.ca
Update: Germany Recognized Price Source
Summary ... Read More
04
Feb2015
PMPRB
The PMPRB has released its January 2015 NEWSletter
Topics covered in the NEWSletter include:
Final 2014 CPI-Based Price-Adjustment Factors: The final CPI figures for 2014 are now available. Of note:
The actual CPI-based price-adjustment factor for 2 year (2012) and 3 year (2011) are lower than forecast. As a result, some manufacturers/patentees may ... Read More
14
Nov2014
Included in this edition are:
PMPRB Town Hall Meeting
PMPRB Staff held a Town Hall meeting on October 1 at the Ottawa Convention Centre. Discussions involved PMPRB Staff taking a fresh look at the organization’s vision and mandate, potential new strategic priorities for the PMPRB and how to operationalize them moving forward. ... Read More